Physician profile
Ryan Morrison
NPI 1760702120
$2,020.30
in general payments reported to CMS, 2019-2025
33 companies · $868 in 2025
The $868 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.77 · 2020: $16.57 · 2022: $105 · 2023: $335 · 2024: $685 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $303.21 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $259.49 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $178.09 | 2024-2025 | Airsupra, Farxiga |
| Amgen INC. | $134.90 | 2024-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $125.60 | 2023-2025 | Eterna, Freestyle Libre 3 |
| Abbvie INC. | $124.52 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $63.46 | 2024-2025 | Rexulti |
| Dexcom, INC. | $61.03 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $60.83 | 2023-2025 | Veozah |
| Davol INC. | $49.12 | 2023 | Phasix Mesh |
| Janssen Pharmaceuticals, INC | $48.79 | 2023 | Xarelto |
| Exact Sciences Corporation | $48.41 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $44.98 | 2025 | |
| Organon LLC | $43.33 | 2022-2023 | Nexplanon |
| Corium, LLC | $41.80 | 2023-2024 | Azstarys, Adlarity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $39.05 | 2025 | Stelara, Simponi Aria, Tremfya |
| Axsome Therapeutics, INC. | $36.90 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $35.70 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $33.57 | 2024-2025 | |
| Pulmonx Corporation | $30.94 | 2022 | |
| Xeris Pharmaceuticals, INC. | $29.92 | 2023-2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $29.70 | 2023-2024 | Vaxneuvance, Gardasil 9, Vaqta |
| Esperion Therapeutics, INC. | $23.25 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $22.29 | 2025 | Inspire |
| Dynavax Technologies Corporation | $22.25 | 2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.18 | 2025 | |
| Lundbeck LLC | $18.21 | 2025 | Rexulti |
| Amarin Pharma, INC. | $16.57 | 2020 | |
| Shield Therapeutics INC | $16.11 | 2025 | |
| Irhythm Technologies, INC. | $15.95 | 2024 | Zio Monitor, Zio Xt Patch |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.